Literature DB >> 8663025

Heat shock protein 84 forms a complex with mutant p53 protein predominantly within a cytoplasmic compartment of the cell.

B Sepehrnia1, I B Paz, G Dasgupta, J Momand.   

Abstract

Cellular DNA damage results in the increased expression and accumulation of the p53 tumor suppressor protein within the nucleus which leads to cell cycle arrest or apoptosis. In some cases, however, wild-type p53 and some mutant forms of p53 reside in the cytoplasm of cancer cells. To understand the mechanism responsible for its cytoplasmic retention, studies were undertaken to determine if unique proteins form a complex with mutant p53 within the cytoplasm of transformed cells. One protein, with an apparent molecular mass of 92 kDa (p92), was observed to form a complex with a temperature-sensitive mutant p53 (TSp53(Val-135)) in the cytoplasm of transformed rat embryo fibroblasts at the non-permissive temperature. p92 copurified with TSp53(Val-135) on a p53-specific immunoaffinity column and a gel filtration column. The protein was purified to homogeneity and identified as hsp84 by partial amino acid sequence analysis. hsp84 is a member of the hsp90 class of proteins. At the non-permissive temperature, TSp53(Val-135) and hsp84 colocalized in the cytoplasm near the nuclear envelope. At the permissive temperature, TSp53(Val-135) resides in the nucleus and expresses a "wild-type like" conformation. Under these conditions hsp84 continued to reside in the cytoplasm and little or no hsp84 formed a complex with p53. The results suggest that hsp84 binds mutant p53 in a spatial and/or conformation dependent manner.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8663025     DOI: 10.1074/jbc.271.25.15084

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  27 in total

Review 1.  Heat shock factor function and regulation in response to cellular stress, growth, and differentiation signals.

Authors:  K A Morano; D J Thiele
Journal:  Gene Expr       Date:  1999

2.  The Hsp90 chaperone complex A potential target for cancer therapy?

Authors:  Beatrice D Darimont
Journal:  World J Gastroenterol       Date:  1999-06       Impact factor: 5.742

Review 3.  Geldanamycin: the prototype of a class of antitumor drugs targeting the heat shock protein 90 family of molecular chaperones.

Authors:  H J Ochel; K Eichhorn; G Gademann
Journal:  Cell Stress Chaperones       Date:  2001-04       Impact factor: 3.667

Review 4.  HSP90 at the hub of protein homeostasis: emerging mechanistic insights.

Authors:  Mikko Taipale; Daniel F Jarosz; Susan Lindquist
Journal:  Nat Rev Mol Cell Biol       Date:  2010-06-09       Impact factor: 94.444

5.  ATP binding to Hsp90 is sufficient for effective chaperoning of p53 protein.

Authors:  Dawid Walerych; Malgorzata Gutkowska; Marcin P Klejman; Bartosz Wawrzynow; Zuzanna Tracz; Milena Wiech; Maciej Zylicz; Alicja Zylicz
Journal:  J Biol Chem       Date:  2010-08-05       Impact factor: 5.157

6.  17-N-Allylamino-17-demethoxygeldanamycin induces a diverse response in human acute myelogenous cells.

Authors:  Jennifer M Napper; Vincent E Sollars
Journal:  Leuk Res       Date:  2010-06-19       Impact factor: 3.156

Review 7.  HSP90AB1: Helping the good and the bad.

Authors:  Michael Haase; Guido Fitze
Journal:  Gene       Date:  2015-09-07       Impact factor: 3.688

8.  Complexity of Hsp90 in organelle targeting.

Authors:  Constantinos Prassinos; Kosmas Haralampidis; Dimitra Milioni; Despina Samakovli; Konstantinos Krambis; Polydefkis Hatzopoulos
Journal:  Plant Mol Biol       Date:  2008-03-27       Impact factor: 4.076

9.  Perturbation of Hsp90 interaction with nascent CFTR prevents its maturation and accelerates its degradation by the proteasome.

Authors:  M A Loo; T J Jensen; L Cui; Y Hou; X B Chang; J R Riordan
Journal:  EMBO J       Date:  1998-12-01       Impact factor: 11.598

10.  ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo.

Authors:  B Panaretou; C Prodromou; S M Roe; R O'Brien; J E Ladbury; P W Piper; L H Pearl
Journal:  EMBO J       Date:  1998-08-17       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.